NPHC
NUTRA PHARMA CORPstockOTC
nutra pharma corporation operates as a biotechnology company specializing in the acquisition, licensing, and commercialization of pharmaceutical products and technologies for the management of neurological disorders, cancer, autoimmune, and infectious diseases. the company carries out basic drug discovery research and clinical development, and also seeks strategic licensing partnerships to reduce the risks associated with the drug development process. currently, nutra pharma offers several drug products for sale for the treatment of pain: nyloxin, the first over-the-counter (otc) pain reliever clinically proven to treat moderate to severe (stage 2) chronic pain, and nyloxin extra strength, the only non-narcotic and non-addictive treatment for severe (stage 3) pain. see: www.nyloxin.com nutra pharma also offers pet pain-away: a product aimed at treating moderate to severe chronic pain in companion animals. pet pain-away is specifically indicated to treat pain from hip dysplasia, arthrit
| Period | Price | Date | Change | Beta |
|---|---|---|---|---|
| 3M | 0.00 | 2026-07-01 | -66.67% | -1591.810 |
| 5Y | 0.00 | 2021-10-05 | -96.77% | -92.689 |
NUTRA PHARMA CORP (OTC:NPHC) stock price today is $0.00, and today's volume is 100,000. NPHC is up 0.000% today. The 30 day average volume is 310,789. NPHC market cap is $709,974 with 7.10B shares outstanding.